Long-Term Systemic Exposure to Rotenone Induces Central and Peripheral Pathology of Parkinson’s Disease in Mice

Shinki Murakami, Ikuko Miyazaki, Ko Miyoshi, Masato Asanuma

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disease with motor and non-motor symptoms that precede the onset of motor symptoms. Rotenone is often used to induce PD-like pathology in the central nervous system (CNS) and enteric nervous system (ENS). However, there is little or no information on the temporal changes in other neural tissues and the spread of pathology throughout the entire body organs. Here, we recorded the serial immunohistochemical changes in neurons and glial cells of the striatum, substantia nigra (SN), olfactory bulb (OB), thoracic cord (ThC) and ascending colon (AC) induced by 1-, 3- and 6-week administration of rotenone (50 mg/kg/day) infused subcutaneously in C57BL mice using an osmotic pump. Rotenone exposure for 3 or 6 weeks caused neurodegeneration in the striatum, whereas neuronal damage was seen in the SN and OB only after 6 weeks. Moreover, rotenone induced neurodegeneration in the myenteric plexus of AC but not in ThC. Rotenone also activated glial cells before any apparent neurodegeneration in the CNS but not in the ENS. Our results demonstrated that subcutaneous administration of rotenone can cause progressive neurodegeneration in the OB and AC, in addition to the nigrostriatal pathway, and temporal differential glial activation, and that these changes do not spread retrogradely from OB or ENS to nigrostriatal pathway. The results suggested that the different vulnerability of neurons to the neurotoxic effects of rotenone administrated subcutaneously are due to glial activation in these neural tissues.

Original languageEnglish
Pages (from-to)1165-1178
Number of pages14
JournalNeurochemical Research
Volume40
Issue number6
DOIs
Publication statusPublished - Apr 18 2015

Fingerprint

Rotenone
Pathology
Parkinson Disease
Neurology
Olfactory Bulb
Enteric Nervous System
Ascending Colon
Neuroglia
Substantia Nigra
Neurons
Spinal Cord
Central Nervous System
Chemical activation
Neurodegenerative diseases
Tissue
Myenteric Plexus
Inbred C57BL Mouse
Neurodegenerative Diseases
Pumps

Keywords

  • Central nervous system
  • Glial cells
  • Parkinson’s disease
  • Peripheral nervous system
  • Rotenone

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Biochemistry

Cite this

Long-Term Systemic Exposure to Rotenone Induces Central and Peripheral Pathology of Parkinson’s Disease in Mice. / Murakami, Shinki; Miyazaki, Ikuko; Miyoshi, Ko; Asanuma, Masato.

In: Neurochemical Research, Vol. 40, No. 6, 18.04.2015, p. 1165-1178.

Research output: Contribution to journalArticle

@article{d775d1b4a47140f9bb09a54e8bff53db,
title = "Long-Term Systemic Exposure to Rotenone Induces Central and Peripheral Pathology of Parkinson’s Disease in Mice",
abstract = "Parkinson’s disease (PD) is a progressive neurodegenerative disease with motor and non-motor symptoms that precede the onset of motor symptoms. Rotenone is often used to induce PD-like pathology in the central nervous system (CNS) and enteric nervous system (ENS). However, there is little or no information on the temporal changes in other neural tissues and the spread of pathology throughout the entire body organs. Here, we recorded the serial immunohistochemical changes in neurons and glial cells of the striatum, substantia nigra (SN), olfactory bulb (OB), thoracic cord (ThC) and ascending colon (AC) induced by 1-, 3- and 6-week administration of rotenone (50 mg/kg/day) infused subcutaneously in C57BL mice using an osmotic pump. Rotenone exposure for 3 or 6 weeks caused neurodegeneration in the striatum, whereas neuronal damage was seen in the SN and OB only after 6 weeks. Moreover, rotenone induced neurodegeneration in the myenteric plexus of AC but not in ThC. Rotenone also activated glial cells before any apparent neurodegeneration in the CNS but not in the ENS. Our results demonstrated that subcutaneous administration of rotenone can cause progressive neurodegeneration in the OB and AC, in addition to the nigrostriatal pathway, and temporal differential glial activation, and that these changes do not spread retrogradely from OB or ENS to nigrostriatal pathway. The results suggested that the different vulnerability of neurons to the neurotoxic effects of rotenone administrated subcutaneously are due to glial activation in these neural tissues.",
keywords = "Central nervous system, Glial cells, Parkinson’s disease, Peripheral nervous system, Rotenone",
author = "Shinki Murakami and Ikuko Miyazaki and Ko Miyoshi and Masato Asanuma",
year = "2015",
month = "4",
day = "18",
doi = "10.1007/s11064-015-1577-2",
language = "English",
volume = "40",
pages = "1165--1178",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Long-Term Systemic Exposure to Rotenone Induces Central and Peripheral Pathology of Parkinson’s Disease in Mice

AU - Murakami, Shinki

AU - Miyazaki, Ikuko

AU - Miyoshi, Ko

AU - Asanuma, Masato

PY - 2015/4/18

Y1 - 2015/4/18

N2 - Parkinson’s disease (PD) is a progressive neurodegenerative disease with motor and non-motor symptoms that precede the onset of motor symptoms. Rotenone is often used to induce PD-like pathology in the central nervous system (CNS) and enteric nervous system (ENS). However, there is little or no information on the temporal changes in other neural tissues and the spread of pathology throughout the entire body organs. Here, we recorded the serial immunohistochemical changes in neurons and glial cells of the striatum, substantia nigra (SN), olfactory bulb (OB), thoracic cord (ThC) and ascending colon (AC) induced by 1-, 3- and 6-week administration of rotenone (50 mg/kg/day) infused subcutaneously in C57BL mice using an osmotic pump. Rotenone exposure for 3 or 6 weeks caused neurodegeneration in the striatum, whereas neuronal damage was seen in the SN and OB only after 6 weeks. Moreover, rotenone induced neurodegeneration in the myenteric plexus of AC but not in ThC. Rotenone also activated glial cells before any apparent neurodegeneration in the CNS but not in the ENS. Our results demonstrated that subcutaneous administration of rotenone can cause progressive neurodegeneration in the OB and AC, in addition to the nigrostriatal pathway, and temporal differential glial activation, and that these changes do not spread retrogradely from OB or ENS to nigrostriatal pathway. The results suggested that the different vulnerability of neurons to the neurotoxic effects of rotenone administrated subcutaneously are due to glial activation in these neural tissues.

AB - Parkinson’s disease (PD) is a progressive neurodegenerative disease with motor and non-motor symptoms that precede the onset of motor symptoms. Rotenone is often used to induce PD-like pathology in the central nervous system (CNS) and enteric nervous system (ENS). However, there is little or no information on the temporal changes in other neural tissues and the spread of pathology throughout the entire body organs. Here, we recorded the serial immunohistochemical changes in neurons and glial cells of the striatum, substantia nigra (SN), olfactory bulb (OB), thoracic cord (ThC) and ascending colon (AC) induced by 1-, 3- and 6-week administration of rotenone (50 mg/kg/day) infused subcutaneously in C57BL mice using an osmotic pump. Rotenone exposure for 3 or 6 weeks caused neurodegeneration in the striatum, whereas neuronal damage was seen in the SN and OB only after 6 weeks. Moreover, rotenone induced neurodegeneration in the myenteric plexus of AC but not in ThC. Rotenone also activated glial cells before any apparent neurodegeneration in the CNS but not in the ENS. Our results demonstrated that subcutaneous administration of rotenone can cause progressive neurodegeneration in the OB and AC, in addition to the nigrostriatal pathway, and temporal differential glial activation, and that these changes do not spread retrogradely from OB or ENS to nigrostriatal pathway. The results suggested that the different vulnerability of neurons to the neurotoxic effects of rotenone administrated subcutaneously are due to glial activation in these neural tissues.

KW - Central nervous system

KW - Glial cells

KW - Parkinson’s disease

KW - Peripheral nervous system

KW - Rotenone

UR - http://www.scopus.com/inward/record.url?scp=84930870619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930870619&partnerID=8YFLogxK

U2 - 10.1007/s11064-015-1577-2

DO - 10.1007/s11064-015-1577-2

M3 - Article

C2 - 25894684

AN - SCOPUS:84930870619

VL - 40

SP - 1165

EP - 1178

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 6

ER -